bgoodmanfsc.github.io

CTDN Common Data Model

The CTDN Common Data Model (CDM) is an open community data standard, designed to standardize the structure and content of clinical trial data, particularly inclusion and exclusion data to enable efficient matching of patients to clinical trials.

In addition to the inclusion and exclusion criteria, we are working to include fields for additional enrichment of clinical trial records that would improve the accessibility of these trials to a diverse audience and increase their capacity to assess participation.

This site will be used to share the current status of the CTDN Common Data Model and to solicit updates and improvements to the model from the members of the Clinical Trial Distribution Network’s working group as well as outside contributors.

The Clinical Trial Distribution Network is managed by PFMD. If you would like to join our group please fill out this form to learn more.

If you want to suggest an update or addition to the CTDN Common Data Model please open an issue. In addition, a Google Sheet of the tables below can be found at this link for either comment or further suggested edits.


The following model is being proposed for usage in the pilot version of the Clinical Trial Distribution Network. We are open to all contributions or suggested edits to this data model.

Inclusion / Exclusion Criteria

Entity Data Category Data Type Parameters Example
NCT Number Trial String None NCT01980823
CT Name - Official Research Title Trial String None Metformin & Atorvastatin Before Surgery to Study Their Effect on Cancer Cells
CT Description - Brief Description of Research Trial String None The purpose of this study is to determine the effects of combining metformin and atorvastatin treatment in patients with newly diagnosed breast cancer during the interval between breast biopsy and surgery. This study is designed to assess whether tumor proliferation, as measured by the natural log expression of Ki-67 staining of breast tumor cells, is reduced following approximately 2 weeks of treatment with the combination of metformin plus atorvastatin in patients with newly diagnosed breast cancer.
Age - Required Age of the Patient Inclusion and Exclusion Integer 1 to 120 45
Stage - Stage of Disease Inclusion and Exclusion Array Stage 1 to Stage 4 Stage 2
Biomarker Status - Select Biomarker Inclusion and Exclusion Boolean TBD HER2
Gender - Required Gender of the Patient Inclusion and Exclusion Boolean Male, Female Male
Phase - Phase of the Clinical Trial Trial Array Phase 1, Phase 2, Phase 3 Phase 2
Origin Company - Primary Sponsor of the Research Trial String None Roche
Recruitment Status - Still recruiting or not Trial Boolean Recruiting, Not Recruiting Recruiting
Location Trial String To be divided into sub types Jean Francois Leemans 34, Auderghem Brussels 1160
Cancer Type Inclusion and Exclusion Array Cancer Types - Per Indication Breast Cancer
Cancer SubType Inclusion and Exclusion Array Cancer Sub Types - Per Indication Triple-Negative
Presence of Metastases Inclusion and Exclusion Boolean True, False False
Treatments Inclusion Boolean True, False True
Treatments Exclusion Array TBD per Indication Chemotherapy, Immunotherapy, Hormonal Therapy,
Performance Status Inclusion Boolean ECOG performance status of 0 or 1 ECOG performance status of 0
Performance Status Exclusion Boolean    

Plain Language Summary

Entity Data Category Data Type Parameters Example
Purpose of the Study Plain Language String None To study the effects of metformin and atorvastin on breast cancer cells.
Who is it for Plain Language String None Women with stage DCIS, I, stage II, or stage III breast cancer.
What is involved Plain Language String None You will receive the following: Metformin and atorvastatin, by mouth, daily, for 2 weeks prior to surgery”
How can I learn more Plain Language String or URL None See below
Resource Plain Language String None BreastCancer.org
Link Plain Language url None Link to PLS
Visits Required per Month Plain Language Integer 1 - 10 2

CTDN Parser of Inclusion and Exclusion Criteria

This repository and effort is working in collaboration with an effort to further advance the use of ML to parse inclusion and exclusion criteria in clinical trials, building on the work originally started by Facebook and further extended by our working group partner Roche.